Keywords : Colon Cancer, colorectal cancer, cancer, Rectal cancer, Adenoma
The colon cancer pipeline has grown as pharmaceutical industry players are attracted by the high incidence and success of other developers. Cytotoxics will remain an integral part of treatment, but with key brands expected to come off patent over the projection period and the approval of new therapies, treatment of this growing industry is set to evolve.Disease o...
More »
Search ReportLinker
The Largest Collection of Market Research Reports
» 1.2 Million Industry Reports
» 450,000 Company Profiles
» 850,000 Market Briefings
» 40,000 Country Guides
From +200,000 authoritative sources
The colon cancer pipeline has grown as pharmaceutical industry players are attracted by the high incidence and success of other developers. Cytotoxics will remain an integral part of treatment, but with key brands expected to come off patent over the projection period and the approval of new therapies, treatment of this growing industry is set to evolve.Disease overview assessing, etiology, risk factors, screening procedures, and patient key market segments In-depth analysis of most common treatment types according to stage at diagnosis and patient characteristicsAnalysis of physician prescribing trends in the seven major industry s across all stages of diseaseAnalysis of possible future treatment trends with regard to targeted therapies and companion diagnosticsThe standard of care for Stage I–III colon cancer is based around surgical resection. Advanced Stage II and Stage III tumors often require additional therapy in combination with surgery. FOLFOX accounts for 50% of the Stage IIIb industry and is the preferred adjuvant chemotherapy regimen in all major pharmaceutical industries, except the UK.First-line treatment of metastatic colon cancer is based on chemotherapy. Bevacizumab plus FOLFOX remains the most prescribed first-line regimen in less cost-conservative industries. However, in almost all pharmaceutical industry s FOLFOX remains the chemotherapy of choice over FOLFIRI despite similar clinical efficacy in the metastatic setting.Datamonitor’s survey indicated that the use of targeted therapies in the first- and second-line settings will increase. Increasing pressure to demonstrate cost-effectiveness of drugs and anticipated approval of new targeted therapies means the use of companion diagnostics will play an increasingly important role in the treatment of colon cancer.Gain insight into the treatment strategies and prescribing trends of 126 physicians treating colon cancer across the seven major industry sExcel deliverable contains extensive treatment trees for each disease stage and country, including percentages and patient numbersAssess colon cancer sector opportunity by identifying where treatment options are not fulfilling patient needs and how physicians select drugs
Pathology Industry in the United Kingdom
OVERVIEW•Catalyst
•Summary
EXECUTIVE SUMMARY•Strategic scoping and focus
•Datamonitor key findings
•Related reports
DISEASE DEFINITION AND DIAGNOSIS•Disease definition - Colorectal cancer is the third most common tumor type and cause of cancer-related death in both men and women
- The only differentiator between colon cancer and rectal cancer is primary tumor location
•Etiology - Adenomas are precursors to the majority of colorectal cancer cases
- Inherited and environmental factors are instrumental in the etiology of colorectal cancer
•Symptoms - Change in bowel habits is the principle symptom of colorectal cancer
•Prognosis - Survival rates for colorectal cancer patients still lag behind those in other high-incidence indications
•Presentation and diagnosis - Screening reduces colorectal cancer incidence and mortality
•Influences on diagnosis and treatment rates - Screen for Life: National Colorectal Cancer Action Campaign
- In 2012 the "Be clear on cancer" campaign was launched in the UK
•Referral patterns - Referral is dictated by stage at diagnosis and treatment approach
PATIENT SEGMENTATION•Stage distribution - The American Joint Committee on Cancer TNM classification system has replaced the older Dukes' staging system
CURRENT TREATMENT OPTIONS•Overview of the available drug classes
•Stage I–III - Treatment type
- Prescribing trends
•Stage IV - Treatment type
- Prescribing trends: first-line
- Prescribing trends: second line and third line
•Local and distant relapse - Local and distant relapse rates
- Treatment and prescribing trends: local relapse
- Treatment and prescribing trends: distant relapse
•Future changes in therapy - Targeted therapies and companion diagnostics
BIBLIOGRAPHY•Journal papers
•Websites
•Datamonitor reports
•Other
APPENDIX A•Physician data
APPENDIX B•Contributing experts
•Conferences attended
•Report methodology
TABLES•Table: Colon cancer 5-year survival rates, by stage at diagnosis, 2001–07
•Table: Leading treatments for colon cancer across the seven major industries, 2011
•Table: Survey respondents across the seven major industries, by country and physician type, 2011
FIGURES•Figure: Relative sensitivity and specificity of different colorectal cancer screening tests
•Figure: Distribution of colon cancer patients across the seven major industries, by stage, 2011
•Figure: Percentage and number of Stage III patients with Stage IIIa, IIIb, and IIIc colon cancer in the seven major industries, 2011
•Figure: Percentage of Stage I–III patients receiving each treatment type in the seven major industries, 2011
•Figure: Number of Stage II–III patients receiving adjuvant chemotherapy, by country, 2011
•Figure: Top three chemotherapy regimens used in the adjuvant treatment of Stage IIIb in each of the seven major industries, 2011
•Figure: Percentage of Stage IV patients receiving each type of treatment in the seven major industries, 2011
•Figure: Top three regimens used in the first-line treatment of Stage IV colon cancer in each of the seven major industries, 2011
•Figure: Number of Stage IV patients receiving chemotherapy neoadjuvant, adjuvant, or both, by country, 2011
•Figure: Top three regimens used adjuvantly with surgery for first-line treatment of Stage IV colon cancer in each of the seven major industries, 2011
•Figure: Number of Stage IV patients receiving additional lines of therapy across the seven major industries, 2011
•Figure: Top three regimens used for second-line treatment of Stage IV colon cancer in each of the seven major industries, 2011
•Figure: Top three regimens used for third-line treatment of Stage IV colon cancer in each of the seven major industries, 2011
•Figure: Percentage of Stage I–III colon cancer patients experiencing local or distant relapse across the seven major industries, 2011
•Figure: Top three regimens used for treatment of local relapse colon cancer patients in each of the seven major industries, 2011
•Figure: Top three regimens used for treatment of first-line distant relapse colon cancer patients in each of the seven major industries, 2011
•Figure: Top three regimens used for the treatment of second-line distant relapse colon cancer patients in each of the seven major industries, 2011
•Figure: Top three regimens used for the treatment of third-line distant relapse colon cancer patients in each of the seven major industries, 2011
•Figure: Physician opinion regarding the role of companion diagnostics in increasing the uptake of targeted therapies in colon cancer in the seven major industries, 2011
Companies mentioned
Chattem, Inc., Hutchison 3G UK Limited, Merck KGaA, Omnicom Group Inc., Schindler Holding Ltd.
